430 related articles for article (PubMed ID: 30970204)
21. Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis.
Yang H; Wang J; Zhang X; Zhang Y; Qin ZL; Wang H; Luo XY
JAMA Dermatol; 2019 May; 155(5):585-593. PubMed ID: 30916723
[TBL] [Abstract][Full Text] [Related]
22. Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor.
Yosipovitch G; Gold LF; Lebwohl MG; Silverberg JI; Tallman AM; Zane LT
Acta Derm Venereol; 2018 Apr; 98(5):484-489. PubMed ID: 29363715
[TBL] [Abstract][Full Text] [Related]
23. Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis.
Paton DM
Drugs Today (Barc); 2017 Apr; 53(4):239-245. PubMed ID: 28492291
[TBL] [Abstract][Full Text] [Related]
24. 2-Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis.
Ciaravino V; Coronado D; Lanphear C; Chanda S
J Dermatol Sci; 2017 Aug; 87(2):116-122. PubMed ID: 28416366
[TBL] [Abstract][Full Text] [Related]
25. Treatment of psoriasis with crisaborole.
Lee EB; Lebwohl MG; Wu JJ
J Dermatolog Treat; 2019 Mar; 30(2):156-157. PubMed ID: 29812961
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities.
Spergel JM; Blaiss MS; Lio P; Kessel A; Cantrell WC; Takiya L; Werth JL; O'Connell MA; Zang C; Cork MJ
Allergy Asthma Proc; 2021 Sep; 42(5):425-431. PubMed ID: 34474712
[No Abstract] [Full Text] [Related]
27. Evaluating crisaborole as a treatment option for atopic dermatitis.
Ramachandran V; Cline A; Feldman SR; Strowd LC
Expert Opin Pharmacother; 2019 Jun; 20(9):1057-1063. PubMed ID: 31002539
[TBL] [Abstract][Full Text] [Related]
28. A retrospective study: Application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor.
Pao-Ling Lin C; Gordon S; Her MJ; Rosmarin D
J Am Acad Dermatol; 2019 May; 80(5):1451-1453. PubMed ID: 30395914
[No Abstract] [Full Text] [Related]
29. Crisaborole (Eucrisa) for Mild to Moderate Atopic Dermatitis.
Castelli G; Schaffer M
Am Fam Physician; 2018 Sep; 98(6):379-380. PubMed ID: 30215912
[No Abstract] [Full Text] [Related]
30. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis.
Eichenfield LF; Call RS; Forsha DW; Fowler J; Hebert AA; Spellman M; Stein Gold LF; Van Syoc M; Zane LT; Tschen E
J Am Acad Dermatol; 2017 Oct; 77(4):641-649.e5. PubMed ID: 28823881
[TBL] [Abstract][Full Text] [Related]
31. Current and emerging topical therapies for atopic dermatitis.
Udkoff J; Waldman A; Ahluwalia J; Borok J; Eichenfield LF
Clin Dermatol; 2017; 35(4):375-382. PubMed ID: 28709568
[TBL] [Abstract][Full Text] [Related]
32. Off-Label Therapeutic Potential of Crisaborole.
Makins C; Sanghera R; Grewal PS
J Cutan Med Surg; 2020; 24(3):292-296. PubMed ID: 32133868
[TBL] [Abstract][Full Text] [Related]
33. Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis.
Simpson EL; Yosipovitch G; Bushmakin AG; Cappelleri JC; Luger T; Ständer S; Tom WL; Ports WC; Zielinski MA; Tallman AM; Tan H; Gerber RA
Acta Derm Venereol; 2019 Jul; 99(9):756-761. PubMed ID: 30896779
[TBL] [Abstract][Full Text] [Related]
34. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.
Bissonnette R; Pavel AB; Diaz A; Werth JL; Zang C; Vranic I; Purohit VS; Zielinski MA; Vlahos B; Estrada YD; Saint-Cyr Proulx E; Ports WC; Guttman-Yassky E
J Allergy Clin Immunol; 2019 Nov; 144(5):1274-1289. PubMed ID: 31419544
[TBL] [Abstract][Full Text] [Related]
35. Crisaborole: A new and effective nonsteroidal topical drug for atopic dermatitis.
Kailas A
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28834023
[No Abstract] [Full Text] [Related]
36. Crisaborole (Eucrisa) for atopic dermatitis.
Med Lett Drugs Ther; 2017 Feb; 59(1515):34-35. PubMed ID: 28222061
[No Abstract] [Full Text] [Related]
37. Phosphodiesterase 4 inhibitors.
Zebda R; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S43-S52. PubMed ID: 29248522
[TBL] [Abstract][Full Text] [Related]
38. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.
Ahmed A; Solman L; Williams HC
Br J Dermatol; 2018 Mar; 178(3):659-662. PubMed ID: 29205284
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers of response to topical crisaborole in patients with mild/moderate pediatric atopic dermatitis from minimally invasive tape strip transcriptome.
Fishbein AB; Mukherji J; Demczuk M; Buranosky B; Osborn J; Moreno C; LaRoche D; Paller AS; Lu KQ
J Am Acad Dermatol; 2024 Mar; 90(3):629-632. PubMed ID: 37924950
[No Abstract] [Full Text] [Related]
40. Ex vivo (human skin) and in vivo (minipig) permeation of propylene glycol applied as topical crisaborole ointment, 2.
Thombre A; Tse S; Yeoh T; Chen R; North R; Brown M
Int J Pharm; 2020 Feb; 576():118847. PubMed ID: 31759994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]